Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
A phase 1/2 trial of HRS-8080, Trastuzumab rezetecan, SHR-A2009 and Adebrelimab in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.
Overview
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT06222879 by Shandong Suncadia Medicine Co., Ltd., with 350 participants planned, started 2024-02-20 and due to reach its primary completion in 2026-10-31. Interventions recorded: HRS-8080; SHR-A1811, HRS-8080; SHR-A2009 and SHR-A2009; SHR-1316.
Similar pages
not linked directly; found by shared links- TrialA Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shares SHR-A2009, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialClinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
Shares HRS-8080, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
Shares Trastuzumab rezetecan, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.